FLT3 and acute myeloid leukemia: A previous analysis of a FLT3‐ITD+ R/R AML patient subgroup from the CHRYSALIS study who achieved CRc with 120‐mg or 200‐mg gilteritinib demonstrated longer survival in MRD‐negative (MRD−) patients than in MRD‐positive (MRD+) patients over a 1‐ to 2‐year period.9